Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3

BACKGROUND: Stimulating antitumor immunity by blocking programmed death-1 (PD-1) or its ligand (programmed death-ligand 1 (PD-L1) is a promising antitumor therapy. However, numerous patients respond poorly to PD-1/PD-L1 blockade. Unresponsiveness to immune-checkpoint blockade (ICB) can cast signific...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Young Min, Khan, Pragya P, Wang, Hong, Tsai, Wen-Bin, Qiao, Yanli, Yu, Bo, Larrick, James W, Hu, Mickey C-T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663085/
https://www.ncbi.nlm.nih.gov/pubmed/34887262
http://dx.doi.org/10.1136/jitc-2021-002772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663085/
https://www.ncbi.nlm.nih.gov/pubmed/34887262
http://dx.doi.org/10.1136/jitc-2021-002772

Ejemplares similares